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Mass Spectrometry of Human Leukocyte
Antigen Class I Peptidomes Reveals Strong
Effects of Protein Abundance and Turnover on
Antigen Presentation*□S
Michal Bassani-Sternberg‡, Sune Pletscher-Frankild§, Lars Juhl Jensen§,
and Matthias Mann‡§¶
HLA class I molecules reflect the health state of cells to
cytotoxic T cells by presenting a repertoire of endoge-
nously derived peptides. However, the extent to which the
proteome shapes the peptidome is still largely unknown.
Here we present a high-throughput mass-spectrometry-
based workflow that allows stringent and accurate iden-
tification of thousands of such peptides and direct deter-
mination of binding motifs. Applying the workflow to
seven cancer cell lines and primary cells, yielded more
than 22,000 unique HLA peptides across different allelic
binding specificities. By computing a score representing
the HLA-I sampling density, we show a strong link be-
tween protein abundance and HLA-presentation (p <
0.0001). When analyzing overpresented proteins – those
with at least fivefold higher density score than expected
for their abundance – we noticed that they are degraded
almost 3 h faster than similar but nonpresented proteins
(top 20% abundance class; median half-life 20.8h versus
23.6h, p < 0.0001). This validates protein degradation as
an important factor for HLA presentation. Ribosomal, mi-
tochondrial respiratory chain, and nucleosomal proteins
are particularly well presented. Taking a set of proteins
associated with cancer, we compared the predicted im-
munogenicity of previously validated T-cell epitopes with
other peptides from these proteins in our data set. The
validated epitopes indeed tend to have higher immuno-
genic scores than the other detected HLA peptides. Re-
markably, we identified five mutated peptides from a hu-
man colon cancer cell line, which have very recently been
predicted to be HLA-I binders. Altogether, we demon-
strate the usefulness of combining MS-analysis with im-
munogenesis prediction for identifying, ranking, and
selecting peptides for therapeutic use. Molecular & Cel-
lular Proteomics 14: 10.1074/mcp.M114.042812, 658–673,
2015.
The highly polymorphic Human Leukocyte Antigen class I
(HLA-I)1 genes are encoded by three loci (HLA-A, B, and C) in
a gene-rich region on chromosome 6. They produce up to six
unique cell surface receptors that bind and present the so-
called HLA class I peptidome, which consists of peptides
derived from proteolysis of intracellular proteins. Their func-
tion is to reflect the health state of the body’s cells to CD8
cytotoxic T cells. During thymic maturation T cells that react
to self-peptides are eliminated (1), leaving T cells with the
capability to recognize peptides from viruses and bacteria.
This recognition is interpreted as a danger signal, leading to
removal of infected cells. Transformed, preneoplastic and
cancer cells also tend to display atypical self-peptides from
mutated or excessively expressed self-proteins, known as
tumor associated antigens (TAAs). Although HLA-I molecules
are indispensable in prevention of disease, they also pose a
substantial health problem by causing allergies (2), life-threat-
ening autoimmune diseases (3), and the often fatal rejection of
donor organs because of recognition of both major and minor
histocompatibility antigens (4).
Finding the rules for peptide generation and selection is
regarded as the most important open issue in the field of
HLA-I biology by leading experts (5). Although the antigen
presentation pathway is well characterized, it is still unclear
how basic properties such as protein abundance, turnover,
and subcellular localization influence and shape the HLA-I
presented peptidome (6–10). One expectation is that protein
abundance should correlate with presentation (11), but previ-
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ous studies have reported conflicting and contradicting re-
sults that mostly argue against a strong link (6, 7, 10, 12, 13).
It is also not fully understood why only some HLA-sampled
self-peptides from cancer antigens spontaneously activate T
cells, whereas others do not.
The majority of HLA-I peptides are derived from protea-
somal degradation (5). Although the proteasome generates an
excess of peptides, only some have the required sequence
motifs for HLA binding, resulting in a selective sampling of
available peptides (14). The presented peptides are typically
nine amino acids long, but the length can range from eight to
15. The high degree of genetic variance of HLA-I receptors
translates into allele-specific peptide-binding motifs defined
by anchor positions, which are usually the second and the last
positions in a peptide (15). Each cell has around 200,000
cell-surface-expressed HLA complexes, which bind about
10,000 unique peptide sequences (16). The affinity of a pep-
tide toward the presenting HLA molecule does not correlate
strongly with its immunogenicity, and neither does the num-
ber of presented HLA complexes (17). Instead, the most ro-
bust predictor of peptide immunogenicity appears to be the
number of potential reactive T-cell clones (17–19).
The longer the source protein, the higher the chances it will
contain sequences that fit to a certain HLA motif, which would
inflate the representation of longer proteins regardless of bi-
ological role. Furthermore, some HLA-I peptide sequences
can be mapped to multiple proteins, potentially causing a
problem in determining the number of observed HLA peptides
per protein (13). This illustrates that careful accounting of
the potentially and actually presented HLA peptides is im-
portant in properly delineating trends in propensity of pep-
tide presentation.
In cancer immunotherapy, T cells can be directed against
tumors, based on the pattern of cancer associated HLA pep-
tides. Therefore, there is great interest in determining the
identity of these immunogenic peptides. Bioinformatic meth-
ods that attempt to predict HLA peptides of cancer proteins of
interest are easily accessible and most commonly used. They
typically score sequences with respect to proteasomal deg-
radation, transport into the ER via the transporter associate
with antigen processing (TAP) and binding to different HLA-I
alleles (20). However, their precision success is modest (21,
22). The second approach is to directly capture the naturally
presented peptides using mass spectrometry; however, this
requires the relevant biological sample and sophisticated in-
struments and workflows, which have become accessible
only recently for large-scale work (23–28). Although identifi-
cation of cancer associated HLA peptides by MS, if per-
formed stringently, establish the in vivo existence of the pep-
tide, it still does not guarantee that it will elicit a potent T-cell
response, which is required for further development into ther-
apeutics (29). Therefore, like in the case of in silico predicted
peptides, the immunogenicity of the peptides must in any
case be tested empirically.
We here present a rich and high confidence HLA-I pep-
tidome, established by applying state-of-the-art mass-spec-
trometric techniques on a collection of seven cell lines. We
investigate how abundance affects the propensity of proteins
to be presented as measurable HLA peptides and whether or
not there are specific protein classes that are overrepresented
even independent of abundance. Likewise, we explore how to
use in silico immunogenicity tools on the set of identified HLA
peptides from cancer-associated proteins, with a view to
select vaccine candidates.
EXPERIMENTAL PROCEDURES
Cell Lines and Antibodies—JY, SupB15WT, HCC1143, HCC1937,
and HB95 cells were maintained in RPMI 1640 medium and HCT116
cells in DMEMmedium. SupB15RT cells were grown with the addition
of 1 M imatinib to the medium (Cayman Chemical, Ann Arbor, MI).
Primary fibroblast cells were a kind gift from Dr. Stern-Ginossar
(UCSF). W6/32 monoclonal antibodies were purified from the growth
medium of HB95 cells that were grown in CELLine CL-350 flask
(Wilson Wolf Manufacturing Corporation, New Brighton, MN) using
Protein-A Sepharose (Invitrogen, Camarillo, CA). HLA-I types were
determined using high-resolution genotyping (Center for Human Ge-
netics and Laboratory Medicine, Martinsried, Germany) except for JY
and SupB15 for which the information was obtained from (27) and
(30), respectively (Table I).
Purification of HLA-I Complexes—HLA-I peptidomes were ob-
tained from three to four biological replicates per cell line. HLA-I
complexes were purified from about 5  108 cell pellets after lysis
with 0.25% sodium deoxycholate, 0.2 mM iodoacetamide, 1 mM
EDTA, 1:200 Protease Inhibitors Mixture (Sigma), 1 mM PMSF, and
1% octyl--D glucopyranoside (Sigma) in PBS at 4°C for 1 h. The
lysates were cleared by 30 min centrifugation at 40,000  g. We
immunoaffinity purified HLA-I molecules from cleared lysate with the
W6/32 antibody covalently bound to Protein-A Sepharose beads
(Invitrogen, Camarillo, CA), because covalent binding of W6/32 anti-
body to the beads improves the purity of the eluted HLA-I complexes,
diminishes co-elution of the antibodies that otherwise overload the
C-18 cartridges, and enables the reuse of the column. This affinity
column was washed first with 10 column volumes of 150 mM NaCl, 20
mM TrisHCl (buffer A), 10 column volumes of 400 mM NaCl, 20 mM
TrisHCl, 10 volumes of buffer A again, and finally with seven column
volumes of 20 mM TrisHCl, pH 8.0. The HLA-I molecules were eluted
at room temperature by adding 500 l of 0.1 N acetic acid, in total
seven elutions for each sample. Small aliquots of each elution fraction
were analyzed by 12% SDS-PAGE to evaluate the yield and purity of
the eluted HLA-I.
Purification and Concentration of HLA-I Peptides—Eluted HLA-I
peptides and the subunits of the HLA complex were loaded on
Sep-Pak tC18 (Waters, Milford, MA) cartridges that were prewashed
with 80% acetonitrile (ACN) in 0.1% trifluoroacetic acid (TFA) and
with 0.1% TFA only. After loading, the cartridges were washed with
0.1% TFA. The peptides were separated from the much more
hydrophobic HLA-I heavy chains on the C18 cartridges by eluting
them with 30% ACN in 0.1% TFA. They were further purified using
a Silica C-18 column tips (Harvard Apparatus, Holliston, MA) and
eluted again with 30% ACN in 0.1% TFA. The peptides were
concentrated and the volume was reduced to 15 l using vacuum
centrifugation. For MS analysis, we used 5 l of this highly enriched
HLA peptides.
LC-MS/MS Analysis of HLA-I Peptides—HLA peptides were sep-
arated by a nanoflow HPLC (Proxeon Biosystems, Thermo Fisher
Scientific, Bremen, Germany) and coupled on-line to a Q Exactive
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mass spectrometer (31) (Proxeon Biosystems, Thermo Fisher Scien-
tific) with a nanoelectrospray ion source (Proxeon Biosystems). We
packed a 20 cm long, 75 m inner diameter column with ReproSil-Pur
C18-AQ 1.9 m resin (Dr. Maisch GmbH, Ammerbuch-Entringen,
Germany) in buffer A (0.5% acetic acid). Peptides were eluted with a
linear gradient of 2–30% buffer B (80% ACN and 0.5% acetic acid) at
a flow rate of 250 nl/min over 90 min. Data was acquired using a
data-dependent “top 10” method, which isolated them and fragment
them by higher energy collisional dissociation (HCD). We acquired full
scan MS spectra at a resolution of 70,000 at 200 m/z with a target
value of 3e6 ions. The ten most intense ions were sequentially iso-
lated and accumulated to an AGC target value of 1e5 with a maximum
injection time of generally 120 ms, except in a few cases where we
used 250 ms to increase signal of the fragments. In case of unas-
signed precursor ion charge states, or charge states of four and
above, no fragmentation was performed. The peptide match option
was disabled. MS/MS resolution was 17,500 at 200 m/z. Fragmented
m/z values were dynamically excluded from further selection for 15 or
20 s.
Mass Spectrometry Data Analysis of HLA Peptides—We employed
the MaxQuant computational proteomics platform (32) version
1.3.10.15. Andromeda, a probabilistic search engine incorporated in
the MaxQuant framework (33), was used to search the peak lists
against the UniProt database (86,749 entries, June 2012) and a file
containing 247 frequently observed contaminants such as human
keratins, bovine serum proteins, and proteases. N-terminal acetyla-
tion (42.010565 Da) and methionine oxidation (15.994915 Da) were
set as variable modifications. The second peptide identification op-
tion in Andromeda was enabled. The enzyme specificity was set as
unspecific. Andromeda reports the posterior error probability and
false discovery rate, which were used for statistical evaluation. A false
discovery rate of 0.01 was required for peptides. As we are interested
in HLA-I peptide identification rather than the protein identification
common in proteomics, no protein false discovery rate was set.
Likewise, as no sequence specific proteases are involved and pep-
tides do not terminate in certain amino acids such as Arg or Lys, the
special permutation rules in MaxQuant for these amino acids (32)
were not used in creating the decoy database. Possible sequence
matches were restricted to eight to 15 a.a., a maximum peptides
mass of 1500 Da and a maximum charge states of three. The initial
allowed mass deviation of the precursor ion was set to 6 ppm and the
maximum fragment mass deviation was set to 20 ppm. We enabled
the “match between runs” option, which allows matching of identifi-
cations across different replicates that belongs to the same cell line,
in a time window of 0.5 min and an initial alignment time window of 20
min. From the “peptide.txt” output file produced by MaxQuant, hits to
the reverse database and contaminants were eliminated. The result-
ing list of peptide is provided in supplemental Table S1.
Total Proteome Sample Preparation, MS Measurement, and Data
Analysis—From the cell lines JY, HCT116, HCC1143, and HCC1937
proteins were digested by the FASP method (34). The proteomic data
from SupB15WT and SupB15RT cells was provided by R. D’souza. In
that data, proteins were also digested by the FASP method but
separated into three SAX fractions as described (35). For the fibro-
blasts, we digested proteins in solution in guanidine-chloride buffer
and separated them into three SCX fractions (36). For all of the above
cases, we cleaned and concentrated 5 g of the peptides on a C18
based StageTip (37), before LC-MS/MS measurement.
Peptides were separated on a 50 cm reversed phase column (75
m inner diameter, packed in-house with ReproSil-Pur C18-AQ 1.9
m resin (Dr. Maisch GmbH)) over a 120 or 240-min gradient of
5–60% buffer B (0.1% (v/v) formic acid and 80% (v/v) acetonitrile)
using the Proxeon Ultra EASY-nLC system (Thermo Fisher Scientific).
The LC system was coupled on-line with a Q Exactive instrument
(Thermo Fisher Scientific) via a nano-electrospray source. Full scans
were acquired in the Orbitrap mass analyzer with resolution 70,000 at
200 m/z. For the full scans, 3e6 ions were accumulated within a
maximum injection time of 20 ms and detected in the Orbitrap ana-
lyzer. The five or ten most intense ions with charge states  two were
sequentially isolated to a target value of 1e5 with a maximum injection
time of 120 ms and in a few cases a fixed injection time of 60 ms was
used. Normalized collision energy was 25% for fragmentation and
resolution was 17,500 at 200 m/z (38).
Raw data analysis for proteomics data sets was performed using
MaxQuant with the same version and similar settings as above, with
the following alterations. Strict trypsin specificity was required allow-
ing up to two missed cleavages. Carbamidomethylation of cysteine
(57.021464) was set as fixed modification. Minimum required peptide
length was set to seven amino acids. A false discovery rate of 0.01
was required for peptides and for proteins in these proteomics ex-
periments. Calculated proteins intensities from MaxQuant “protein-
Groups” output file were used for estimation of abundance and are
provided for each of the cell lines in supplemental Tables S2–S8.
Predicting HLA-I Peptides from JY Cells—We observed 2874 pep-
tides from 2368 proteins for the JY cells of which 2875 could be
mapped to distinct expressed protein sequences. By default, tools for
prediction of HLA-binding provide 9-mer peptides. Of the original
2875 uniquely observed HLA-binding peptides about 61% (1741)
were 9-mers and we used these for comparisons to predictions. We
employed the prediction tool NetMHCcon1.0 (39) to estimate the
HLA-binding for A02 and B7 alleles to the associated source proteins
for the 9-mer peptide set. This led to a total of 1,188,744 9-mer
peptides associated with prediction values allowing the computation
of ROC curve accessing the power of the prediction.
Of the observed 1741 9-mer peptides, we were able to include
1732 in the computation of the ROC curves and the derived AUC
values. The inconsequential loss of 0.5% of the observe peptides was
caused by incomplete matching between protein IDs from the Max-
Quant output and UniProt IDs.
The suggested HLA-I alleles of the cancer peptides are indicated
with their prediction binding scores in affinity Kd values, which were
generated using NetMHC 3.4 for the common alleles (All A alleles,
B*07:02, B*08:01, B*18:01, B*40:01, B45:01, B*51, Cw*04:01, Cw*05:
01, Cw*06:02, Cw*07:01, Cw*07:02, and Cw*14:02), and for the re-
maining alleles using NetMHCcons 1.0 Servers (39, 40).
Gibbs Clustering of HLA-I Peptidomes—Gibbs clustering analysis
was performed using the publicly available GibbsCluster-1.0 Server
tool (41). We used 9-mer HLA-I peptides as input using the default
settings without alignment, 1–6 number of clusters, and the default
threshold score of zero for “discarding to trash” as described in (41). We
compared the resulting motifs to the known and predicted motifs of the
HLA-I alleles using the MHC motif viewer (42) and the SYFPEITHI
database (43).
HLA-I peptide sampling density. HLA-I peptides that originate from
proteins for which we had no data on expression levels were omitted
from the computation of HLA-I sampling density. About 8–11% of all
presented peptides can be mapped back to several expressed source
protein sequences and counting such nonunique peptides could cre-
ate a bias toward peptides commonly found in the human proteome
and toward larger groups of homologous proteins, protein families,
and genes with many isoforms. Although overall only about one in 10
HLA-I peptides have more than one protein source, we find that
18–26% of those proteins with at least one mapped HLA-I peptides
contain another HLA-I peptide that is shared with other protein se-
quences. It is estimated that only about 20% of potential peptides are
sufficiently cleaved during proteasomal degradation (44) and it is
therefore reasonable to expect that only a subset of proteins will
contribute to the production of peptide because of favorable down-
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stream sequence motifs, significant expression and an adequate
degradation frequency. We define a presentation density for each
protein sequence based the number of observed HLA-I peptides
divided by the number of 9 mers contained in the protein sequence.
Then we corrected for cases in which the peptide occurred in different
proteins as described in detail in Online Supplemental Experimental
Procedures.
To estimate which proteins are actually more presented than
expected, we modeled the expected value of presented HLA-p
densities from the length of the protein (L) and the measured protein
abundance (A) as: D  D(protein A)  F(L, A). To determine F, we
first divide the proteins into bins of proteins with similar abundance,
calculate the average HLA-p density for each bin, and then fit a
sigmoid function to this. The resulting function is used to calculate
the expected HLA-p density given A and L for each protein.
RESULTS
Mass Spectrometry-Based Capturing of the HLA Class I
Peptidome—Elucidating global properties of the presented
proteome requires analysis of HLA-I peptidomes across
different cell types and multiple alleles. To this end, we de-
veloped a workflow employing a robust protocol for the puri-
fication of HLA-I peptides and their identification using a
state-of-the-art quadrupole Orbitrap mass spectrometer (Q
Exactive) and the MaxQuant environment (Fig. 1). In contrast
to earlier studies that focused on one or few selected alleles
across a single cell type (27, 28, 45), we analyzed seven
primary and cancer cell lines expressing a total of seven
different HLA-A alleles, ten HLA-B alleles, and nine HLA-Cw
alleles (Table I). Remarkably, just 5  108 cells per biological
replicate turned out to be sufficient to obtain high coverage of
HLA peptides in a relatively short measurement time of 2 h per
replicate. Although recently published studies applied a permis-
sive FDR threshold of 5% or more (26, 27), we wished to restrict
the analysis to peptides identified with high certainty. Using a
stringent FDR of 1%, we reached a high median Andromeda
identification score of 123. With a more permissive 5% FDR
threshold, the median Andromeda scores is reduced to 98,
whereas the total number of identified peptides increases to
49,011. (For comparison, Andromeda scores are generally
about threefold larger than Mascot scores (33); the median
identification score of our peptidomics data set is thus equiva-
lent to a Mascot score of about 41.) We identified from 2758 to
5324 peptides sequences in HCC1143 and fibroblast cells,
respectively, and a total of 22,244 sequence-distinct peptides
from all seven cell lines. More than 93% of the peptides have
the typical length of HLA-I peptides, that is nine to 11 amino
acids. The measured MS signals of the peptides span four
orders of magnitude. Although most of the peptides are doubly
charged, we were also able to accurately identify singly charged
ions, which constitute about 15% of the peptidome (supple-
mental Table S1 and Fig. 2).
Unique repertoires of peptides are presented on the surface
of cells that express different sets of HLA alleles according to
the specificity of their binding motifs. As expected, we ob-
served that cells expressing similar alleles, such as fibroblast
and HCC1937 cells, shared drastically more peptide se-
quences than cells expressing different set of alleles, like
fibroblast and HCT116 cells (Fig. 3A). We also found a higher
correlation between the peptidome intensities from cells that
share HLA-I alleles, as highlighted by the analysis of the
isogenic cells SupB15WT and SupB15RT (resistance to ima-
tinib treatment). The quantitative reproducibility of the pep-
tidomes was excellent (R2  0.83–0.91) between biological
replicates and very good (R2 0.71–0.76) between these two
isogenic lines (Fig. 3B). This demonstrates both the robust-
ness of our protocol and the stability of the cellular presenta-
tion machinery, which sampled the same peptides sequences
and therefore the same source proteins in cells with similar
genetic background.
Unbiased and Direct Definition of HLA-I Binding Motifs—
HLA-I peptides are characterized by their typical binding mo-
tifs. In an attempt to obtain the motifs directly from the pep-
tidome data, without the need for genotyping information, we
clustered the peptides by sequence similarity. We expected
to find up to six motifs and fewer in case of motif redundancy,
homozygosity, or abolished expression of one or more alleles.
Using the Gibbs clustering algorithm (41) we resolved the
motifs and their relative contribution to the total presentation
from cells expressing only three alleles such as JY cells, and
more alleles like HCC1143 and HCC1937 (Fig. 4A, and
supplemental Data). In most cases the motifs of HLA-Cw
alleles could not be resolved, probably because of their low
expression levels, and because of redundancy in their spec-
ificities to HLA-A and B alleles. For cell types that share one of
their alleles, we should detect the corresponding binding mo-
tives in both and this was indeed the case. For example,
similar motifs were obtained for HLA-A*23:01 in HCC1937
and the fibroblast cells, for HLA-A*03:01 in the fibroblast and
SupB15 cells, and for HLA-A*02:01 in JY and HCT116 cells.
Moreover, we could assign the motif for the poorly defined
HLA-Cw*06:02 allele (42, 43, 46) based on 358 peptides se-
quences identified from HCC1143 cells.
Accurate Identification of the Naturally Presented Pep-
tidomes—To quantitatively assess the ability of our protocol
to enrich for HLA-I binders and discriminate against potential
co-eluting contaminants, we predicted the HLA binding for
the presented peptides of the two HLA-I alleles expressed in
JY cells using the proteins expressed in this cell line as a set
of input sequences) (Fig. 4B, and detailed description in Ex-
perimental Procedures). JY cells specifically express A*02:01
and B*07:02. (They also express very low levels of HLA-
Cw*07:02, but because the binding motif of HLA-Cw*07:02
overlaps considerably with the motifs of A*02:01 and B*07:02,
only these motifs where qualitatively observed in the Gibbs
clustering analysis.) We evaluate the agreement between the
observed peptidome of JY cells and the predicted peptidome
as a receiver operating characteristic (ROC) curve (Fig. 4C).
We summarize the ROC curve as the area under the curve
(AUC) value, which ranges from 0.5 for random agreement to
High Accuracy MS-based Identification of Human Leukocyte Antigen Class I Peptidomes
Molecular & Cellular Proteomics 14.3 661
1.0 for perfect agreement. The resulting AUC value of 0.975
reflects excellent agreement, meaning that the predictor con-
firmed that the vast majority of isolated peptides fit the HLA-
A*02:01 and HLA-B*07:02 motifs. A threshold of predicted
affinity 500 nM is commonly applied for retrieving weak
binders, and yielded 1579 out of the 1732 identified peptides
(91.2%). A total of 1133 (65%) of the peptides are predicted to
be strong binders (50 nM) (Fig. 4B).
A: Sample preparation
B: Liquid chromatography - mass spectrometry
C: Identification of HLA-I peptides
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FIG. 1. Schematic overview of HLA-I peptidomics. A, Sample preparation. HLA-I complexes were immunoaffinity purified from cells lysates
using anti-HLA-I (W6–32) antibody cross-linked to Protein-A Sepharose beads. HLA-I peptides were purified from the heavy chain based on
their hydrophobicity using a C-18 column. B, Liquid chromatography and mass spectrometry. The enriched mixtures of HLA-I peptides were
measured on a quadrupole Orbitrap mass spectrometer (Q Exactive), resulting in high resolution and high mass accuracy at the MS and MS/MS
levels. C, Identification of HLA-I peptides. HLA-I peptides were analyzed with MaxQuant software, using an unspecific search, allowing the
identification of peptides with one, two, and three charge states. In total, 22,244 unique HLA-I peptides were identified with a median
identification score of 123 using a threshold of 1% FDR at the peptide level. D, HLA-I consensus binding motifs. Using the GibbsCluster tool
the consensus binding motifs were defined from the identified peptides sequences.
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TABLE I
List of cell lines and their tissue origin used for HLA-I peptidome study and their genotypic information
Cell line Tissue origin HLA-A HLA-B HLA-Cw
JY B-cells EBV transformed HLA-A*02:01 HLA-A*02:01 HLA-B*07:02 HLA-B*07:02 HLA-Cw*07:02 HLA-Cw*07:02
SupB15 B-cell leukemia HLA-A*03 HLA-A*11 HLA-B*51 HLA-B*52 HLA-Cw*12:04 HLA-Cw*14:02
HCC1143 Basal like breast cancer HLA-A*31:01 HLA-A*31:01 HLA-B*35:08 HLA-B*37:01 HLA-Cw*04:01 HLA-Cw*06:02
HCC1937 Basal like breast cancer HLA-A*23:01 HLA-A*24:02 HLA-B*07:02 HLA-B*40:01 HLA-Cw*03:04 HLA-Cw*07:02
HCT116 Colon carcinoma HLA-A*01:01 HLA-A*02:01 HLA-B*45:01 HLA-B*18:01 HLA-Cw*05:01 HLA-Cw*07:01


























































































































































































FIG. 2. Properties of the HLA-I peptidomes data set obtained from seven cell lines. A, Number of HLA-I peptides identified in each
peptidome sample. B, Length distribution of HLA-I peptides. C, Intensities of HLA peptides span over four orders of magnitudes. D,
Identification score distribution of HLA-I peptides for each of the charge states. E, Number of HLA-I peptides that were identified with the
different charge states.
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To estimate the purity of the isolated peptidomes further,
we introduced noise in silico, which will imitate the presence
of impurities in our peptidomes. As the most likely contami-
nating components are peptides originating from nonspecific
degradation of co-eluting proteins, we randomly added 9-mer
peptides from the source proteins of the HLA-I peptides to the
list of observed 9-mer peptides from JY cells. We did this from
0 to 100%, in steps of 5%, and repeated the computation of
the resulting ROC curve and AUC values. The addition of
10%, 25%, and 50% random peptides reduced the AUC
values to 0.931, 0.877, and 0.816, respectively (Fig. 4D and
4E). These analyses show quantitatively how AUC values are
affected by impurities and here they revealed that this impurity
must be minimal in our data set (much less than 5%).
Computing Presentation of Expressed Proteins from HLA-I
Peptide Counts—Because cell lines that express unique sets
of HLA-I alleles have few presented peptides in common, it is
difficult to directly compare peptide intensities and estimate
HLA-I sampling. The measured intensities of HLA-I peptides
reflect a combination of their intracellular processing, their bind-
ing affinities, and their compatibility with MS detection (ioniza-
tion and fragmentation). Therefore, even HLA-I peptides that
originate from the same protein within one sample can differ
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FIG. 3. HLA-I peptidomes are highly reproducible. A, Cells expressing similar alleles shared more peptide sequences than cells expressing
different set of alleles. Very low quantitative reproducibility of peptidomes isolated from cells expressing different set of alleles. B, Quantitative
reproducibility of the peptidomes isolated from SupB15WT and SupB15RT. The reproducibility of the peptidomes was excellent (R2  0.83
–0.91) between biological replicates and very good (R2  0.71 – 0.76) between the two isogenic lines.
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proteins, which are a source for several detected HLA-I pep-
tides (Fig. 5A and 5B and supplemental Tables S2–S8). This
allowed us to investigate the correlation between the number of
HLA-I peptides (rather than their MS-intensities) and expression
level of their source proteins, which was measured in an inde-
























































































































































































































































































































































































































































































































































































































































































































FIG. 4. High confident identification of purified HLA-I peptides. A, Defining motifs directly from the mixture of identified peptides. Gibbs
clustering analysis was performed for the purified 9-mer HLA-I peptides from the different cell lines. The motifs of the isogenic cell lines
SupB15WT and SupB15RT cells were identical; therefore the results are shown only for SupB15WT. For each initial number of clusters the
information content of the alignment is shown as a bar plot, where the size of each block within a bar is proportional to the size of a given
cluster. The blue star marks the number of clusters that were selected based on the optimal fitness (higher KLD values) and minimum outliers,
and their sequence logo plots are shown with the number of HLA-I peptides in each cluster and the assigned HLA-I alleles that fit each cluster.
Binding motifs were calculated for each cluster from the frequency of the amino acids (AA) in positions P1 to P9 in the peptides sequences
(see Supplemental Data). Frequency of more than 30% was classified as a dominant anchor motif (bold), more than 20% as a strong motif
(underline), and more that 10% as a weak motif. B, Confirming the accurate identification of the observed peptides by predicting their affinity
to the expressed alleles. We predicted using NetMHCcon (39) the binding affinity (maximal predicted binding affinity; HLA-A*02:01 and
HLA-B*07:02) of the peptidome data set of 9-mer peptides from JY cells, and estimated the performance of the predictor using the expressed
proteins as the set of input sequences. We compared the default affinity score 500 nM to include weak binders and the high affinity score
of50 nM to restrict to strong binders only. C, The computed Receiver Operating Characteristic (ROC) curve for the binding affinity to the HLA-I
based on the predicted 9-mer epitopes from JY cells. The AUC (area under the curve) value is 0.975. D, Evaluating the deterioration in the ROC
analysis when introducing noise of randomly selected 9-mer sequences from the expressed proteins. 9-mer peptides were added from 0
to100%, in steps of 5%, to the list of observed 9-mer peptides from JY cells. E, AUC values calculated from ten iterations of noise introduction.
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Although our streamlined workflow enabled analysis of a
very large number of HLA peptides, about 70% of the ex-
pressed proteins were not presented at all in our peptidomics
data set (supplemental Tables S2–S8). Most likely, many of
them are still presented to some extent on the cells surface;
however, in peptide copy numbers that made them inac-
cessible to detection. These nonrepresented proteins are
nevertheless distinguished from the others by the fact that
they present no or undetectable HLA peptides and we set
out to further characterize these proteins in the following
sections.
HLA-I Presentation Correlates Significantly with Protein
Abundance—Because HLA-I peptides originate primarily from
proteasomal cleavage of proteins, a possible expectation
would be that highly abundant proteins lead to more proteins
being degraded per unit of time than less abundant proteins.
Moreover, longer proteins contain more 9-mers and should
therefore give rise to more potential HLA-I binders. Thus, one
FIG. 5. HLA-I sampling for presentation correlates with proteins length, abundance, and half-life. A, HLA-I peptides in proteins as a
function of proteins length. The plot represents the comparison between the number of presented peptides and the length of the source
proteins as detected in proteomic analysis of total cell lysates. The blue line is a running average calculation of the data points. B, HLA-I
peptides in proteins as a function of proteins abundance. The plot represents the comparison between the number of presented peptides and
protein abundance, in Log2(intensity) of their source proteins as detected in proteomic analysis of total cell lysates. Every protein that was
detected in the proteomics analysis in each of the cell lines is presented in the plot according to the number of resulting detected HLA-I.
Therefore, the same protein can be represented in the plot several times in case that it was detected in different intensities and gave rise to
different number of epitopes in each of the cell lines. The blue line is a running average calculation of the data points. C, HLA-I sampling density
(D) correlates with protein abundance. Using a running average, HLA-I sampling density is significantly correlated with the abundance of the
source proteins (p 0.0001). The data was fitted with a trend line (solid line) for each cell line. D, Fold HLA-I sampling density over the expected
sampling (D). For each protein the ratio D/D is represented as a function of protein abundance. The criteria for the selection of overpresented
proteins was set to D5 times larger than the expected HLA-I sampling density (D). E, Unbiased selection of overpresented proteins. An
explanatory plot showing how without correcting for the bias that originates from preferential presentation of highly expressed proteins the
selection of overpresented proteins will result in selecting mainly the abundant proteins. The histogram represents protein abundance. The
emphasized black histogram (5 x trend) shows the protein abundance for the subset of proteins with D5 times larger than the expected HLA-I
sampling density (D), and it has the same shape as the proteome (in gray). The red histogram (biased) illustrates what would happen if D was
a constant (D  0.012), resulting in a biased selection toward highly expressed but not overpresented proteins. F, Presentation efficiency
(D/D) in relation to proteins half-life. Regardless of expression levels, turnover rates measures as half-life values, statistically significant
correlate with presentation, in all cell lines (p  0.001).
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might expect a positive correlation between the number of
measured HLA-I peptides and the abundance and length of
their source proteins, although establishing such a relation-
ship has so far been proven difficult.
First we investigated if there was a relationship between the
length of the protein and the number of presented peptides in
our data set. This clearly the case as can be seen in Fig. 5A
and supplemental Fig. S1A. Similarly, Fig. 5B and supplemen-
tal Fig. S1B establish an unambiguous relationship between
protein abundance and resulting HLA peptides. Next, to
quantify the correlation between presentation and protein
abundance in an unbiased manner, we normalized for protein
length by calculating the HLA-I sampling density (D). For each
source protein we computed D from its count of HLA-I pep-
tides, weighting down shared peptides to eliminate bias (sup-
plemental Experimental Procedures). This analysis revealed a
highly significant correlation between HLA-presentation and
the abundance of the source proteins (p  0.0001) (Fig. 5C).
The figure also reveals that in the cell lines tested, the mean
sampling density of the 20% most abundant proteins was
3.04- to 5.17-fold higher than the mean density of the 20%
least abundant proteins (supplemental Tables S2–S8). Thus
as expected, low abundant proteins will on average be the
source of fewer HLA-I peptides than more abundant proteins.
We further wanted to explore which proteins are more
presented than should be expected from their abundance. To
this end we identified a set of “overpresented” proteins, which
we defined as the proteins with HLA-I sampling density at
least fivefold higher than their expected predicted sampling
density (termed D) given their abundance (D/D5) (Fig. 5D).
This strategy ensured that the protein abundance distribution
of overpresented proteins resembles that of other proteins
(black line in Fig. 5E), whereas this is not the case without this
correction (red line).
Protein Half-Life Correlates with Efficient HLA-I Presenta-
tion—Although we find a clear correlation between protein
abundance and HLA-I sampling rates, about half of the 20%
most abundant proteins are not represented at all in our
peptidomics data set. We focused on these “hidden” proteins
(abundant but not represented) because their absence in the
HLA peptidome is less likely to be caused by the finite detec-
tion capability of our MS-setup. They can only to small extent
be explained by a generally shorter median protein length (311
for the hidden proteins versus 441 for the presented ones). In
search of other factors we noticed that hidden proteins have
longer half-lives. We obtained the half-life for 4066 of the
proteins in our data set from (47). Among these, we identified
154 overpresented proteins for which we were able to find a
corresponding hidden protein with a closely matched abun-
dance and length (154 matched hidden proteins). This match-
ing ensures that any observed difference between the two
sets will not be caused by the small difference in protein
length between hidden and presented proteins or difference
in their abundance. We found that hidden proteins are signif-
icantly longer-lived (median half-life 23.6h) than overpre-
sented proteins (20.8 h, p  4.8E-5) (Fig. 6A).
Extending this analysis, we next correlated the presentation
efficiency (D/D) in relation to turnover rate for the entire data
set. This revealed a statistically significant correlation (p 






















































































FIG. 6. Characterization of overpresented proteins. A, Protein degradation and HLA-I presentation. Hidden proteins, with the same length
and same abundance level, are longer lived than overpresented but also in general longer lived than other highly abundant proteins. From the
top 20% abundant proteins we compared 154 proteins, which were overpresented proteins (D/D5) to balanced set of similar size of hidden
proteins (D  0) with matched expression and protein length. B, Predicting immunogenicity of HLA-I peptides from cancer antigens and from
overpresented proteins. The 229 epitopes from the set of validated cancer antigens are significantly more immunogenic than the 82 HLA-I
peptides from the same proteins which we identified in our peptidomics data set. Overpresented proteins (D/D5) are not more immunogenic
than the rest of the presented peptidome (0D5) both in primary and cancer cell lines.
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sion level, turnover rates influence the level of presentation;
however, without normalizing for protein length and abun-
dance this correlation could not have been resolved (supple-
mental Fig. S1C).
Faster turnover for otherwise matched protein properties
should lead to a higher concentration of HLA peptide precur-
sors, therefore, our statistical association are biologically
plausible.
Preferentially Presented Biological Processes and Cellular
Compartments—We investigated whether overpresented pro-
teins have a shared biological function or cellular localization
that favors their presentation. For each of the cell lines, we
selected the overpresented proteins and used the proteome
expressed in these cells as a customized background set, and
performed gene ontology enrichment analysis using the
DAVID functional annotation tool (48, 49). The significantly
enriched terms (Benjamini-Hochberg corrected p value of 5%
or less) in most of the cell lines regardless of their alleles and
binding motifs are the mitochondrion (all cells except JY and
SupB15RT), ribosome (all cells except JY cells), and the
nucleosome in Supb15WT and SupB15RT cells (supplemen-
tal Tables S2–S8). Specifically, the overpresented mitochon-
drial proteins belong to the NADH dehydrogenase, ATP syn-
thase, and cytochrome oxidase complexes as well as the
mitochondrial ribosomes. The mitochondrial and cytoplasmic
ribosomes were both represented with the large and small
subunits as well as associated proteins.
Prioritizing HLA-I Peptides Via Immunogenicity Prediction—
HLA peptides originating from cancer-associated proteins are
used clinically in turning the immune system toward attacking
the tumor (29, 50–55). The presentation of peptides from
overexpressed, cancer-associated self-proteins is known to
be elevated on cancer cells compared with healthy cell (56,
57). This elevated presentation can break the inherited toler-
ance against self and can lead to antitumor response. A key
challenge in the field is to select the most promising HLA
epitopes even from one candidate protein. Given the large
number of high quality hits from reported cancer-associated
proteins resulting from our workflow, we explored ways to
prioritize them via in-silico methods.
Using a tool that is able to predict immunogenicity of viral
HLA-I peptides (58), we first evaluated if immunogenicity of
cancer and viral peptides follows the same trends employing
the list of 229 immunogenic epitopes from cancer-associated
proteins published in ref (59). The T-cell-defined epitopes
were selected based on their good performance in activating
T cells, hence, we expect them to be the most immunogenic
HLA-I peptides from these proteins. We name them
“epitopes” to distinguish them from other HLA-I peptides we
detected in our study. Our data set contains four known
cancer epitopes from this list, among them well characterized
epitopes from the melanoma-associated antigens family
(MAGE-A1 and MAGE-A3) and 82 more HLA-I peptides from
25 cancer-associated proteins (59) (supplemental Table S9).
We predicted the immunogenicity of the 229 empirically val-
idated immunogenic T-cell epitopes associated with cancer
and compared their scores to the 82 HLA peptides we iden-
tified in our data set (Fig. 6B). We find that T-cell-defined
cancer epitopes are predicted to be significantly more immu-
nogenic than other MS-identified HLA-I peptides that origi-
nate from the same proteins (p  5  106). Based on these
findings, we suggest ranking the experimentally identified
HLA peptides based on their immunogenicity score. For ex-
ample, in our data set we found that peptides that score
higher than 0.15 are the top 20%most immunogenic peptides
(supplemental Table S9).
Serving as a control, HLA-I peptides that originate from the
overpresented proteins (D5) turn out to be less immuno-
genic compared with the cancer epitopes. They also seem to
be slightly less immunogenic than HLA-I peptides from other
presented proteins (0D5), although this difference is not
statistically significant. We conclude that the immunogenicity
of cancer-associated HLA-I peptides can to some extent be
predicted and utilize this to suggest potential new epitopes
(supplemental Table S9).
Direct Identification of Mutated HLA-I Peptides—During re-
vision of this manuscript, a resource of cell line-specific HLA
type and somatic mutations has been published, including
predictions of HLA-I binding peptide sequences that harbor
these mutations (60). In this catalog, 152, 167, and 1903
mutated sequences were predicted to be presented in
HCC1143, HCC1937, and HCT116 cell lines, respectively. We
added these sequences to the list of UniProt proteins used for
the database search, and reanalyzed the peptidomics data
with MaxQuant, again applying the stringent 1% FDR for
peptide identification. We clearly and unambiguously identi-
fied five mutated HLA-I peptides from HCT116 cell line, bear-
ing mutations that were reported to be presented in this
particular cell line (60) (Table II; and supplemental Data 2 for
annotated spectra). All peptides were predicted to be strong
binders with Kd values of less than 150 nM.
DISCUSSION
Although much is known about the antigen presentation
pathway of intracellular proteins, this knowledge has mostly
been derived over several decades from small-scale studies
involving the processing of relatively few proteins, typically of
microbial origin (5). The advent of modern, high performance
proteomics technologies, which has already revolutionized
our ability to identify and quantify complete proteomes, now
promises to allow global, systems-wide investigation of pep-
tides presented to the immune system.
Here we have developed a powerful and streamlined work-
flow for the detection of HLA-I peptides presented by cells.
We took advantage of the new generation of improved mass
spectrometers, specifically the quadrupole-Orbitrap instru-
ment (31), and better approaches to immune purification of
HLA-I peptides (23). The high resolution of the Q Exactive, in
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combination with the HCD fragmentation, enabled an in-
depth and accurate identification of the HLA-I peptidomes,
whereas our purification protocol minimizes unnecessary
steps and is optimized for sensitive, robust, and fast mea-
surements. We used at least 20 times less sample compared
with recently published studies (27, 28); therefore, our work-
flow makes it possible to identify HLA-I peptidomes from
small amounts of sample such as tumors. Furthermore, we
achieve high numbers of HLA-I peptide identifications even in
a single-shot format, drastically reducing measurement time
compared with protocols involving extensive fractionations
(i.e. up to 40 fractions (27, 28, 61)).
A recently published study combines two fragmentation
modes and therefore generates particularly information rich
fragment spectra (EThcD fragmentation method), leading to a
high identification percentage of HLA peptides (28). However,
by its nature, that method is restricted to at least doubly
charged precursors, while we also target singly charged pep-
tides for fragmentation. They comprise about 15% of the data
set reported here, but in our hands they can reach to 40% of
total identified peptides, depending on the amino acids that
restrict the binding motifs.
It in principle possible that our HLA peptide enrichment
protocol would also copurify non-HLA peptides, such as co-
eluting degradation products of cellular proteins. To assess
the presence or absence of such peptides we employed
NetMHCcon (39), a widely used tool to score peptides by their
predicted affinity for selected alleles. We performed this anal-
ysis for the JY cell line because 1) this is the only cell line in our
set that is homozygous for the main alleles (A*02:01 and
B*07:02), 2) the expressed alleles are the best studied one
and predictors have been optimally trained for them, and 3) as
a consequence of the fact that the available receptors only
bind two motifs, the intensity of the HLA peptides is in-
creased. When we predicted the binding affinities of the ex-
perimentally identified peptides from the JY cells to these
alleles, we found that 91% of them had immunologically rel-
evant affinities of better than 500 nM. Of the remaining pep-
tides, many also have appreciable predicted affinities; there-
fore, the level of possible contaminations is likely to be much
less than 10%. Additionally, we modeled the effect of possible
contaminant peptides, which also predicted absence or very
low level of contaminating peptides.
This analysis also implies a robust performance of the pre-
dictor. However, prediction alone cannot yield the in vivo
presented HLA peptidome. For instance, by its nature, the
prediction algorithm does not account for the abundance of
the source proteins; they predict sequences that could not be
presented under physiological conditions, for instance pro-
teins that are expressed at too low levels. Furthermore, these
algorithms generally overpredict: Only about 1:30 predictions
were observed in our data at the default threshold that in-
cludes weak binders. In principle, we could change this ratio
to the still very large ratio of 1:12 by increasing the threshold
to include only the strong binders. However, this is already too
stringent because we then lose 35% of the observed pep-
tides. Conversely, HLA peptides may be present but go un-
detected because of low abundance or unusual peptide prop-
erties or because of the stringent peptide identification
criteria. Therefore the performance of the HLA predictors is
somewhat higher than what we calculate here, which, how-
ever, does not solve the overprediction or false-positive
problem.
Having established that our data reflect the actual pep-
tidome well, we proceeded to estimate HLA-I presentation in
relation to the expressed proteome. We computed the HLA-I
sampling density by counting observed peptides regardless of
their reported intensities. Intensity based computation of the
HLA-I sampling would be biased by the MS compatibility of
the individual peptides because about 61% of source proteins
are singletons, 22% have two epitopes, and the rest three and
more. Therefore, we count the peptides, and then normalize
the count by the length of the source protein, as longer
proteins give rise to more epitopes.
HLA peptide sequences may occur in more than one pro-
tein in the database, complicating analysis and the correct
computation of the HLA-I sampling density. Hoof et al.
excluded these peptides from their analysis (13), yet this may
lead to a bias because abundant proteins have more
epitopes, and therefore they have higher chance to share
epitopes. The solution is to down-weight the contribution of
multiple-target HLA-I peptides in a proper way assuming a
posterior model of cleavage given the peptide is known to be
cleaved at least by one potential sequence.
There have been conflicting reports on how protein abun-
dance influences the degree of presentation. Marginal corre-
TABLE II
List of MS-identified mutated HLA-I peptides purified from HCT116 cell line. Potential mutation bearing peptide sequences were obtained from
(60) and they were added to the UniProt database for MaxQuant search. The mutated positions are marked in bold
Protein Peptide AA change Length
Identification
score
HLA Allele best fit
(NetMHC 3.4 predicted affinity, Kd values in nM)
CHMP7 QTDQMVFNTY p.A324T 10 166 A*01:01 (39), Cw*05:01 (23)
BCL2L13 EEEYPGVTA p.I216V 9 148 B*45:01 (20)
NR1D1 YSDNSNDSF p.G39D 9 134 A*01:01 (36), Cw*05:01 (2)
RBBP7 EERVIDEEY p.N17D 9 116 B*18:01 (149)
UQCRB EEEKFYLEP p.N88K 9 117 B*45:01 (54)
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lations as low as 6% (R2) have been reported (10), whereas a
recent publication found that presented proteins are generally
more abundant than nonsampled (13). On the basis of the fact
that MS signals of the HLA-I ligandome varied greatly even in
the same protein, it has been concluded that it is not possible
to predict the ligand copy number from the overall proteins
copy number, and hence, that there is no clear selection on
the basis of protein properties during antigen processing (27).
A comparison of mRNA levels and peptidome found a weak
link (r  0.32) (8), and another noted that HLA-I binding
peptides are preferentially derived from highly abundant
mRNAs (6). In contrast, it has also been reported that that only
a minority of differentially expressed HLA-peptides originate
from differentially expressed genes (7).
These disagreements have led to speculations about the
involvement of novel biological effects that contribute to the
production of HLA-I binding peptides, such as the DRiPs
hypothesis and the pioneer round of mRNA translation. These
theories suggest that a major source of HLA peptides derived
from premature translation termination or downstream initia-
tion (62, 63), hence there can be effective presentation even in
the near absence of protein expression. However, only few
studies have attempted to rigorously quantify the contribution
of such alternative pathways to the generation of the pep-
tidomes (10, 63–65). No positional bias was found in recently
published studies among DRiPs toward the N terminus or the
C terminus (64, 65). DRiPs were described to originate from
the rapid degradation of “normal” proteins and subunits of
complexes that are produced in excess (64). Our results indi-
cate that high turnover of proteins, many of which are sub-
units of large complexes, enables their efficient presentation.
Here, we propose that the previously reported lack of cor-
relation between presentation and proteins abundance was
largely the result of insufficient statistical and data processing
methods. Using our in-depth and accurate data set, we now
demonstrate a highly statistically significant correlation be-
tween protein abundance and HLA-I sampling density
(p0.0001) indicating a direct mechanistic relationship be-
tween the protein copy number and the tendency to present
peptides derived from them. Two factors enabled us to detect
the clear significant correlation between presentation and ex-
pression of source proteins: the improved computation of
HLA-I sampling density instead of peptide intensities and
employing a method of moving average, which is better suited
to analyze trends in data that are both sparse and dominated
by single numerical values like the many nonpresented pro-
teins, which results in a majority of zeroes.
We further characterized the two extreme states of presen-
tation efficiencies: hidden proteins, which have no detectable
HLA-I peptides in our experimental conditions and proteins
with higher than expected sampling densities. We showed
that abundant proteins without any detectable peptides have
relatively lower turnover rates than the overpresented abun-
dant proteins. Hidden proteins are relatively stable and long-
lived and may not give rise to enough degradation products to
be further processed and presented at a level that we could
detect.
Previous efforts to characterize the cellular localization and
functional properties of the source proteins did not account
for the expression levels of the source proteins (9, 66). Here
we removed this bias and investigated the functional proper-
ties of proteins with higher than expected sampling densities.
In most of the cell lines investigated, mitochondrial proteins,
histones, and ribosomes were presented even in excess of
the degree expected from their abundance. Mitochondrial
proteins are susceptive to oxidative stress-related damage
caused by free radicals, and are routinely replaced to maintain
proper organelle function. Ribosomal proteins are expressed
in excess and a significant fraction of ribosomal proteins,
which are imported into the nucleus, is degraded by the
proteasome (67), which helps to explain their substantial con-
tribution to the HLA-I peptidome (64). Nucleosomes were
shown to turnover multiple times during each cell cycle (68) in
a proteasome mediated degradation (69, 70). In these cases
of high protein turnover, the increased HLA presentation can
most simply be explained by their increased flux through the
proteasome and subsequent parts of the antigen processing
machinery.
Many studies, and especially immunotherapeutic interven-
tions, have for the sake of predictability and simplicity focused
on a limited set of frequently expressed HLA-I alleles with
exceptionally well-characterized motifs (25, 27, 55). Indeed,
this formed a strict inclusion criterion for patients eligible for
receiving experimental cancer vaccines. With the limited per-
formance of MS-based technology that was available when
immunotherapy was emerging into clinical settings, it was
necessary to predict potential cancer epitopes in silico rather
than measure them directly. Even today, HLA-I binding
predictors are used almost exclusively to discover cancer
epitopes. Yet the inevitable high number of false positives,
which we estimated to be around nine out of 10, often carries
a high risk of investing resources on the wrong targets. As we
show here, MS-based workflows now enable accurate detec-
tion of the true and often relatively well-presented epitopes in
great detail. We can resolve binding motifs directly from our
data regardless of genotyping information, a capability that
can be applied to explore alleles with yet unknown motifs. As
a result, new cancer epitope can be identified across different
HLA-binding specificities, as there is no need to only select
donors with particular HLA subtypes. Furthermore, in combi-
nation with prior knowledge of the repertoire of somatic mu-
tations, we identified five HLA-I peptides bearing mutations
with binding specificities to five HLA-I alleles expressed in the
human colon carcinoma HCT116 cell line. Such peptides are
especially prized for developing immunotherapeutics because
they do not occur naturally in the noncancer tissues.
Applying MS-based workflows to clinical tumor samples
will result in similar rich peptidomics data set and hence the
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straightforward identifications of cancer-associated HLA-I
peptides and mutated peptides. Moreover, de novo sequenc-
ing algorithms will enable identification of such peptides with-
out prior knowledge of somatic mutation. However, because
there is no correlation between affinities to the HLA-I allele or
copy number of peptides with immunogenicity (17), neither it
nor HLA-I binding prediction can highlight the most immuno-
genic epitopes to elicit an efficient potent antitumor response.
Instead, in silicomethods can efficiently prioritize the peptides
shown to be presented by mass spectrometry. We propose to
select these candidate epitopes based on: (1) the individual’s
six possible HLA binding motifs and the relative expression
levels of the corresponding receptor in the investigated tumor
sample, (2) the abundance and turnover rate of the source
protein, and (3) the predicted immunogenicity score. In case
no cancer epitopes can be identified from the patient’s tumor,
the resulting peptidome can be used to predict potential
epitopes that fit the more dominantly expressed alleles. We
envision that better immunotherapeutics could be developed
based on wider and more accurate repertoires of HLA-I pep-
tides and that such treatments will be available to a larger
cohort of patients.
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